X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
Australia
South Africa
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125521
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/eli-lilly-forays-into-dermatological-space-with-launch-of-psoriasis-drug/articleshow/98625403.cms?utm_source=contentofinterest&utm_medium=text&utm_campaign=cppst
https://www.prnewswire.com/news-releases/lillys-taltz-ixekizumab-now-available-in-new-citrate-free-formulation-to-reduce-injection-site-pain-for-improved-patient-experience-301601067.html
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125521
http://www.pharmatimes.com/news/nice_backs_lillys_taltz_for_axial_spondyloarthritis_1371749
https://www.prnewswire.com/news-releases/taltz-delivers-more-cumulative-days-with-completely-clear-skin-for-adults-with-psoriasis-compared-to-seven-other-biologics-in-novel-network-meta-analysis-301275567.html
https://endpts.com/sanofi-teams-with-virtual-reality-biotech-on-oral-dupixent-successor/
https://www.fiercepharma.com/pharma/cigna-s-500-gift-to-psoriasis-patients-who-switch-to-lilly-s-taltz-rehearsal-for-humira
https://finance.yahoo.com/news/taltz-ixekizumab-approved-health-canada-190300312.html
https://www.clinicaltrialsarena.com/news/lilly-data-psoriasis-trials/
https://www.prnewswire.com/news-releases/new-data-at-eadv-2020-confirm-taltz-ixekizumab-demonstrates-sustained-long-term-efficacy-in-patients-with-psoriasis-and-psoriatic-arthritis-301162144.html
https://www.biospace.com/article/releases/new-data-at-eadv-2020-confirm-taltz-ixekizumab-demonstrates-sustained-long-term-efficacy-in-patients-with-psoriasis-and-psoriatic-arthritis/
https://www.fiercepharma.com/pharma/express-scripts-axes-novartis-psoriasis-drug-favor-lilly-s-as-discounting-takes-over-analyst
http://www.pharmatimes.com/news/lilly_bags_expanded_eu_approval_for_taltz_1341518
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125521
https://www.fiercepharma.com/pharma/despite-challenges-lilly-sees-bright-things-ahead-2020-and-beyond
https://www.prnewswire.com/news-releases/acr-2019-lilly-presents-positive-new-data-from-coast-x-a-phase-3-study-of-taltz-ixekizumab-in-patients-with-non-radiographic-axial-spondyloarthritis-300954995.html
https://www.fiercepharma.com/pharma/novartis-cosentyx-cues-new-fight-against-eli-lilly-s-taltz-spondyloarthritis-data
https://www.fiercepharma.com/pharma/as-key-meds-deal-lower-pricing-and-new-competition-lilly-can-count-class-expansion-ceo
https://www.prnewswire.com/news-releases/lilly-presents-positive-results-for-taltz-ixekizumab-in-pediatric-patients-with-moderate-to-severe-plaque-psoriasis-at-the-28th-annual-european-academy-of-dermatology-and-venereology-eadv-congress-300937170.html
https://www.fiercepharma.com/pharma/eli-lilly-s-taltz-busts-tremfya-43-skin-clearance-head-to-head-tussle
https://www.fiercepharma.com/pharma/novartis-cosentyx-chases-eli-lilly-s-taltz-new-spondyloarthritis-trial-data
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=125521
https://endpts.com/lillys-taltz-wins-third-approval-this-time-in-patients-with-active-ankylosing-spondylitis/
http://www.pmlive.com/pharma_news/leo_pharma_to_market_astrazenecas_brodalumab_outside_europe_1297760
http://www.pharmatimes.com/news/taltz_trumps_tremfya_in_plaque_psoriasis_study_1297563
https://www.biopharmadive.com/news/lilly-bests-jj-with-implications-for-abbvies-new-immunology-star/560826/
https://www.clinicaltrialsarena.com/news/lilly-taltz-plaque-psoriasis-trial/
https://www.fiercepharma.com/marketing/lilly-s-taltz-bests-j-j-rival-tremfya-head-to-head-psoriasis-tilt
https://www.fiercepharma.com/pharma/abbvie-s-il-23-hopeful-skyrizi-scores-nod-from-england-s-cost-watchdog?utm_source=internal&utm_medium=rss
https://www.fiercepharma.com/pharma/amid-important-launches-lilly-s-bio-medicines-head-shaw-steps-aside
https://www.fiercepharma.com/pharma/crowded-psoriasis-who-could-pick-up-bristol-celgene-s-otezla-at-what-price
https://www.fiercepharma.com/pharma/watch-out-humira-eli-lilly-courting-physicians-blockbuster-topping-taltz-data
https://www.fiercepharma.com/marketing/abbvie-pads-skyrizi-s-blockbuster-potential-positive-2-year-data
https://www.biopharmadive.com/news/lilly-drug-scores-in-phase-2-crohns-study/555359/
https://www.fiercepharma.com/pharma/lilly-s-light-sales-for-trulicity-taltz-prompt-analyst-questions
https://endpts.com/anxious-to-fill-humira-sized-revenue-hole-ahead-of-us-patent-cliff-abbvie-hits-the-ground-running-with-us-skyrizi-approval/
https://www.reuters.com/article/us-lilly-study/lilly-says-taltz-superior-to-humira-in-late-stage-psoriatic-arthritis-trial-idUSKBN1OG1B3
https://www.fiercebiotech.com/biotech/abbvie-builds-case-for-potential-psoriasis-blockbuster-risankizumab-ahead-regulatory?utm_source=internal&utm_medium=rss
https://www.prnewswire.com/news-releases/lilly-announces-initiation-of-ixora-r-head-to-head-trial-comparing-taltz-and-tremfya-in-patients-with-moderate-to-severe-plaque-psoriasis-300709215.html
https://www.prnewswire.com/news-releases/lilly-to-showcase-new-data-at-the-27th-european-academy-of-dermatology-and-venereology-eadv-congress-furthering-innovation-for-patients-with-complex-dermatological-conditions-300709707.html
https://www.fiercepharma.com/pharma-asia/cosentyx-shingrix-and-luxturna-among-48-drugs-china-s-invitation-list-for-approval
https://www.tga.gov.au/prescription-medicines-new-or-extended-uses-registered-medicines
https://www.fiercepharma.com/lilly-s-taltz-infringes-new-genentech-patent-lawsuit-says
https://www.pharmacompass.com/pdf/news/taltzixekizumab-genentech-inc-v-eli-lilly-and-company-1530870200.pdf
https://endpts.com/touting-phiii-success-for-arthritis-drug-taltz-eli-lilly-chases-rival-novartis-in-heated-immunology-race/
https://www.prnewswire.com/news-releases/lilly-announces-positive-top-line-results-for-second-phase-3-study-of-taltz-ixekizumab-in-ankylosing-spondylitis-radiographic-axial-spondyloarthritis-for-tnf-inhibitor-experienced-patients-300673690.html
https://www.prnewswire.com/news-releases/us-dermatologists-report-significant-growth-of-next-generation-psoriasis-biologicsnovartis-cosentyx-eli-lillys-taltz-and-janssens-tremfya-300664999.html
Market Place
Share 
